ER‑100 IND Cleared: What Glaucoma Patients Should Know About the New Partial Reprogramming Trial

What happened and why it matters now

Life Biosciences announced U.S. Food and Drug Administration (FDA) clearance of an investigational new drug (IND) application for ER‑100 on January 28, 2026. The clearance clears the way for the first human study of a controlled, inducible delivery of three Yamanaka factors (OCT4, SOX2, KLF4 — "OSK") to the eye, a partial epigenetic reprogramming approach aimed at restoring younger cellular states in retinal ganglion cells (RGCs) in optic neuropathies such as open‑angle glaucoma (OAG) and non‑arteritic anterior ischemic optic neuropathy (NAION) [Life Biosciences 2026; Nature Biotechnology 2026].

What the Phase 1 trial actually is

The clinical trial is registered as NCT07290244 and is a Phase 1, open‑label, dose‑escalation study focused on safety and immune responses. Key, verifiable design features are:

• Single, unilateral intravitreal injection of ER‑100 (AAV‑based vector delivering inducible OSK) to one eye per participant [ClinicalTrials.gov NCT07290244].
• Three cohorts for a total target enrollment of about 18 participants: two OAG cohorts (low and high dose) and one NAION cohort that will use the dose selected based on OAG safety data [ClinicalTrials.gov NCT07290244; TrialLayer 2026].
• Documented dosing in the registry: low‑dose OAG cohort at 2 × 10^11 viral genomes (vg)/eye and high‑dose OAG cohort at 6 × 10^11 vg/eye; the NAION cohort would receive the dose supported by prior safety data [ClinicalTrials.gov NCT07290244; MedPath mirror].
• OSK expression is designed to be inducible: participants will receive systemic doxycycline to activate expression for approximately 8 weeks (56 days) per protocol language on the registry; the study uses sentinel dosing, staged escalation and oversight by safety review committees [ClinicalTrials.gov NCT07290244; MedPath mirror].
• Follow‑up includes multi‑year safety monitoring (registry summaries state up to ~5 years, aligning with FDA long‑term follow‑up expectations for AAV products) [ClinicalTrials.gov NCT07290244; FDA LTFU 2020].

Why the protocol is designed this way

The trial reflects two pragmatic priorities: first, a safety‑first dose escalation to watch for immune or vector‑related adverse events; second, an inducible expression system so investigators can switch gene expression on for a defined period rather than leave it uncontrolled. These elements mirror the preclinical lineage for the approach: Lu and colleagues used AAV‑delivered, tetracycline‑responsive OSK in mice and reported restoration of youthful gene expression and axon regeneration in retinal injury models while using inducible control in those experiments [Lu et al. 2020]. Nature Biotechnology and other independent reports emphasize that ER‑100 represents the first clinical test of partial epigenetic reprogramming, and therefore the human program is explicitly designed to collect safety and immune data before any efficacy claims are made [Nature Biotechnology 2026].

What this means for glaucoma patients considering trial participation

If you or a loved one has glaucoma and you're thinking about clinical trials, here are practical, evidence‑based points to keep in mind right now:

• Enrollment will be small and selective. Phase 1 trials like NCT07290244 typically enroll limited numbers to assess safety. The registry lists ~18 participants across cohorts, so access will be constrained and subject to eligibility criteria in the official protocol [ClinicalTrials.gov NCT07290244].
• Participation involves an intraocular procedure and systemic antibiotic for activation. The investigational product is given as an intravitreal injection to one eye; OSK expression is activated by doxycycline for about eight weeks under the study protocol. Taking doxycycline outside the trial is not a substitute for participation and is not advised for this purpose [ClinicalTrials.gov NCT07290244].
• Safety monitoring will be prolonged. The study design includes long‑term monitoring consistent with FDA guidance for AAV‑based products, with registry summaries indicating follow‑up for multiple years to detect delayed events [ClinicalTrials.gov NCT07290244; FDA LTFU 2020].
• Unknowns remain about human safety and benefit. Promising mouse data provide a mechanistic rationale, but human safety and efficacy are untested. The trial is explicitly safety‑first and will measure immune responses and other adverse events as primary outcomes before any conclusions on benefit can be drawn [ClinicalTrials.gov NCT07290244; Lu et al. 2020].
• Talk with your glaucoma specialist early. If you’re interested, discuss potential eligibility, standard‑of‑care options, and whether referral centers running the trial are appropriate for evaluation. Only the trial’s informed consent and protocol provide authoritative eligibility and risk information.

How to stay informed and verify details

For verified, up‑to‑date information consult the primary sources: the study registry (ClinicalTrials.gov NCT07290244), the sponsor’s IND announcement, and peer‑reviewed preclinical literature. Useful links include the sponsor press release and the ClinicalTrials.gov record; independent news summaries also reported the IND clearance [Life Biosciences 2026; ClinicalTrials.gov NCT07290244; Nature Biotechnology 2026].

Quick links

• Life Biosciences IND announcement (Jan 28, 2026)
• ClinicalTrials.gov record NCT07290244
• Lu et al., Nature 2020 (preclinical OSK study)

Bottom line: ER‑100’s IND clearance starts the first-in-human safety testing of an inducible partial reprogramming therapy for optic neuropathies. For patients, the immediate priorities are accurate information, careful risk‑benefit conversations with specialists, and watching the trial registry and sponsor updates for enrollment and safety results. The program is explicitly designed to proceed cautiously — safety and long‑term monitoring come first.